In a groundbreaking advancement for biomedical engineering and cellular therapy, researchers at the IRCCS Fondazione Istituto Neurologico Carlo Besta (FINCB) and Politecnico di Milano have successfully coated mitochondria with innovative protective materials without compromising their vital biological functions. Mitochondria, widely recognized as the cellular powerhouses responsible for generating metabolic energy, are notoriously delicate organelles that frequently suffer structural damage or loss of function when modified artificially. This scientific breakthrough demonstrates that these microscopic organelles can be encapsulated with synthetic coatings while fully maintaining their metabolic integrity. The findings open up promising new avenues for targeted organelle therapy and tissue regeneration strategies.
The pioneering study was conducted as part of the ongoing work at the BraiNs joint laboratory, an innovative interdisciplinary facility inaugurated in 2023. Created to bridge the gap between advanced engineering techniques and clinical neurological research, the BraiNs lab unites the medical expertise of the Carlo Besta Neurological Institute with the technical innovations of Politecnico di Milano. This collaborative environment provided the necessary infrastructure to handle the delicate bio-hybrid engineering required for the breakthrough. Scientists involved in the research highlighted that combining materials science with live cellular components presents immense technical hurdles, requiring precise conditions to prevent cellular toxicity.
To achieve this milestone, the scientific team engineered specialized surface materials that interact smoothly with the mitochondrial outer membrane. A major technical obstacle in mitochondrial manipulation has historically been preserving the organelle’s transmembrane potential, which is essential for synthesizing adenosine triphosphate, the fundamental energy currency of cells. Post-treatment evaluation confirmed that the newly coated mitochondria maintained their metabolic activity, oxygen consumption rates, and structural integrity comparable to untreated samples. By successfully cloaking these delicate powerhouses, researchers can shield them from immediate enzymatic degradation or hostile immune responses when introduced into external cellular environments.
The capability to protect and functionalize mitochondria holds profound implications for treating a wide array of neurodegenerative and neuromuscular conditions. Pathologies such as Parkinson’s disease, Alzheimer’s disease, and stroke-induced ischemic injuries are deeply linked to severe mitochondrial dysfunction and cellular energy failure. Through mitochondrial transplantation—delivering healthy, functional organelles directly to affected tissues—clinicians could potentially restore cellular energy balance and reverse tissue damage. The novel protective coating could also be functionalized further to include targeted surface molecules, enabling the modified mitochondria to navigate directly to damaged brain cells.
Looking to the future, the research team plans to transition from in vitro experiments to assessing the performance of coated mitochondria within living cell cultures and animal models. Future investigations will focus on optimizing the long-term stability of the bio-hybrid structures and studying how recipient cells absorb and integrate them. If validated in subsequent preclinical trials, this technology could establish a novel paradigm in nanomedine and organelle-based therapeutics. The success achieved by the BraiNs joint laboratory highlights the immense power of cross-disciplinary collaboration in solving complex biological challenges.
